Clinical Trials Logo

Propranolol clinical trials

View clinical trials related to Propranolol.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05979818 Not yet recruiting - Clinical trials for Non Small Cell Lung Cancer

Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy for Treatment of Advanced Non-small Cell Lung Cancer

BRIO
Start date: December 31, 2023
Phase: Phase 1
Study type: Interventional

This study is a prospective single-center Phase I clinical study in patients with EGFR/ALK/ROS1 driver oncogene negative, and advanced or metastatic NSCLC. This study is to evaluate the efficacy and safety preliminarily in a small-size of propranolol hydrochloride in combination with sintilimab and platinum-based chemotherapy in first-line therapy. Propranolol hydrochloride is a beta- adrenergic blocking agent which is associated with augment of immune cell responses. Propranolol hydrochloride may improve the responses of immune checkpoint inhibitors in treating patients with advanced NSCLC.

NCT ID: NCT05375240 Not yet recruiting - Stroke Clinical Trials

Propranolol on Post Stroke Immune Status and Infection

Start date: June 2022
Phase: Phase 2
Study type: Interventional

Stroke-associated pneumonia (SAP) is one of the important risk factors influencing poor outcomes and death in stroke patients. Over the past two decades, accumulating evidence suggests that post-stroke brain injury mobilizes the adrenergic system, which induces post-stroke immunosuppression and SAP. This study is designed to test the safety and efficacy of an adrenergic β-receptor blocker, propranolol, with or without combination of antibiotics, in reducing SAP in stroke patients. The underlying immune mechanisms will be investigated.